Travere Therapeutics Sees Surge in Sales Following FILSPARI Approval for FSGS
On April 13, 2026, the FDA granted Travere Therapeutics full approval for FILSPARI, a treatment for focal segmental glomerulosclerosis (FSGS). This marked the drug's second full approval, following a previous clearance for IgA nephropathy in 2023. The approval is significant for patients aged 8 and...
